RecruitingAcute Coronary SyndromeStrokeTransient Ischemic Attack
Florbetaben for Imaging of Vascular Amyloid
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.
Sponsor: Ottawa Heart Institute Research Corporation
You may qualify if…
- ✓ 1. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
- ✓ 2. stable symptoms and hemodynamics;
- ✓ 3. age \>/= 18 years;
- ✓ 4. given informed consent.
You may not qualify if…
- ✕ 1. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
- ✕ 2. severe LV dysfunction (EF\<30%);
- ✕ 3. severe valve disease requiring intervention;
- ✕ 4. decompensated heart failure;
- ✕ 5. pregnancy (all women of child bearing potential will have a negative BHCG test;
- ✕ 6. breastfeeding;
- ✕ 7. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.
- ✕ 8. unable to give informed consent;.
Source: ClinicalTrials.gov · NCT06091319 · last updated 2026-05-08